Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD (RELIVE)

Median Technologies

Status

Completed

Conditions

High Risk Cancer

Lung Cancer

Treatments

Device: Median LCS

Study type

Observational

Funder types

Industry

Identifiers

NCT06751576

MT-LCS-004

Details and patient eligibility

About

This is a two arm, randomized, controlled, blinded, multi-case multi reader (MRMC), retrospective study for the evaluation of the efficacy and safety of an AI/ML technology-based CADe/x developed to detect, localize and characterize malignancy score of pulmonary nodules on LDCT chest scans taken as part of a lung cancer screening program.

LDCT DICOM images of patients who underwent routine lung cancer screening will be selected and enrolled into the study. Enrolled scans analyzed by radiologists with the assistance of the Median LCS (formerly iBiopsy) device are compared to the analysis by radiologists without the assistance of the Median LCS device.

Figures of merit for patient level and lesion level detection and diagnostic efficacy will be calculated and compared, sub-class analysis will be performed to ensure device generalizability.

Enrollment

480 patients

Sex

All

Ages

50 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

≥50-80 Years of age;
Current or ex-smoker (>=20 pack years);
Patient screened and surveilled for lung cancer screening following lung cancer screening guidelines (equivalent to United States Preventive Services Task Force (USPSTF) 2021 Criteria);
Received LDCT due to inclusion in high-risk category for lung cancer.

Exclusion criteria

Prior lung resection;
Pacemaker or other indwelling metallic medical devices in the thorax that interfere with CT acquisition;
Patients/images used during AI model development;
Patients with only hilar and/or mediastinal cancer(s);
Patients with only ground glass cancer(s);
Patients with nodules, solid or part-solid >30mm (masses);
Patients that are not accompanied with the required clinical information;
Patients with imaging with any of the following: missing slices, slice thickness >3mm;
Partial cover of the lung.